4.42
Schlusskurs vom Vortag:
$4.86
Offen:
$4.7
24-Stunden-Volumen:
158.70K
Relative Volume:
1.39
Marktkapitalisierung:
$38.27M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-3.4803
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
+8.60%
1M Leistung:
-4.95%
6M Leistung:
-57.90%
1J Leistung:
-68.88%
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KPTI
Karyopharm Therapeutics Inc
|
4.43 | 33.61M | 140.46M | -146.34M | -117.73M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
571.50 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.06 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com
What analysts say about Karyopharm Therapeutics Inc. stockConsistent triple-digit returns - Autocar Professional
Karyopharm Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - jammulinksnews.com
Is Karyopharm Therapeutics Inc. a good long term investmentSuperior stock selection - Autocar Professional
What drives Karyopharm Therapeutics Inc. stock priceBreakneck growth rates - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Will Karyopharm Therapeutics Inc. stock split in the near futureHigh Return Intraday Picks - Newser
HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN
H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns - Investing.com Canada
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
How Karyopharm Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
What makes Karyopharm Therapeutics Inc. stock price move sharplyROI Driven Alerts - beatles.ru
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser
Newton biotech cuts over 50 jobs, and other biotech news - The Business Journals
HC Wainwright Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics: A Liquidity Crossroads with Little Room to Pivot - AInvest
Karyopharm stock tumbles after disclosing failed financing talks By Investing.com - Investing.com South Africa
Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN
Karyopharm's Freefall: What's Driving the Collapse? - AInvest
Karyopharm stock tumbles after disclosing failed financing talks - Investing.com Australia
Karyopharm Therapeutics Inc reducing workforce by about 20% - MarketScreener
Karyopharm Therapeutics Explores Financing and Strategic Options - TipRanks
Karyopharm Therapeutics (KPTI) Receives 'Buy' Rating with $27 Pr - GuruFocus
Analyst Initiates Coverage on Karyopharm (KPTI) with Positive Ou - GuruFocus
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):